© 2002 by European Society of Cardiology
Copyright © 2001, European Society of Cardiology
High plasma concentrations of human urotensin II do not alter local or systemic hemodynamics in man
aClinical Pharmacology Unit, Department of Medical Sciences, University of Edinburgh, Western General Hospital, Edinburgh EH4 2LH, UK
bSchool of Biological Science, G.38 Stopford Building, University of Manchester, Oxford Road, Manchester M13 9PT, UK
d.j.webb{at}ed.ac.uk
* Corresponding author. Tel.: +44-131-537-2006; fax: +44-131-537-2003
Objective: Human urotensin II (hUII) is an endocrine hormone that acts as a potent arterial vasoconstrictor in both in vitro and in vivo studies in animals. We examined, for the first time, the local and systemic hemodynamic response to hUII in man in vivo. Methods: Four healthy male volunteers took part in pilot studies and 11 in definitive studies. Forearm blood flow (FBF) was measured in response to intra-arterial infusion of authentic, biologically active hUII (incremental rates of 0.001–300 pmol min–1) and saline placebo using venous occlusion plethysmography. Blood pressure, heart rate, cardiac output and hUII plasma concentrations were also measured. Forearm studies were repeated in five subjects with inhibition of endothelial mediators using aspirin and a "nitric oxide clamp". Dorsal hand vein diameter was determined by a standard displacement technique in response to local administration of hUII (3–300 pmol min–1) with and without nitric oxide synthase inhibition. Results: There was no significant change in FBF during brachial infusion of saline or hUII (dose range, 0.001 to 300 pmol min–1). A nitric oxide clamp did not unmask vasoactive effects of hUII. Human UII infusions (100 and 300 pmol min–1) significantly increased plasma hUII concentrations from baseline (12±3 pmol l–1) to 106±15 and 307±98 pmol l–1, respectively. Despite high circulating hUII concentrations, no change was seen in systemic hemodynamics and ECGs were unchanged. Human UII had no effect on hand vein diameter (n=6). Conclusions: In contrast to our hypothesised role of hUII, we found no vasoactive responses to hUII in vivo, consistent with recent in vitro studies in human blood vessels, but in contrast to non-human primate studies in vivo. Our data do not support a key role for hUII in the regulation of vascular tone and resting blood pressure in man. However, studies with hUII receptor antagonists are also needed before firm conclusions can be drawn.
KEYWORDS Arteries; Blood pressure; Hemodynamics; Regional blood flow; Veins
2 Present address: Cardiologia, Clinica San Carlo, via Ospedale 21, Paderno Dugnano, Milano, Italy.
1 Present address: Clinical Pharmacology Unit, Addenbrooke's Hospital, University of Cambridge, Cambridge CB2 2QQ, UK.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  P. N. Sidharta, P. L. M. van Giersbergen, and J. Dingemanse Pharmacokinetics and Pharmacodynamics of the Urotensin-II Receptor Antagonist Palosuran in Healthy Male Subjects J. Clin. Pharmacol., October 1, 2009; 49(10): 1168 - 1175. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. D. Leonard, J. P. Thompson, E. L. Hutchinson, S. P. Young, J. McDonald, J. Swanevelder, and D. G. Lambert Urotensin II receptor expression in human right atrium and aorta: effects of ischaemic heart disease Br. J. Anaesth., April 1, 2009; 102(4): 477 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. E. S. Abdel-Razik, R. J. Balment, and N. Ashton Enhanced renal sensitivity of the spontaneously hypertensive rat to urotensin II Am J Physiol Renal Physiol, October 1, 2008; 295(4): F1239 - F1247. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. P. Williams, J. P. Thompson, S. P. Young, S. J. Gold, J. McDonald, D. J. Rowbotham, and D. G. Lambert Nociceptin and urotensin-II concentrations in critically ill patients with sepsis Br. J. Anaesth., June 1, 2008; 100(6): 810 - 814. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. G. Lambert Urotensin II: from osmoregulation in fish to cardiovascular regulation in man Br. J. Anaesth., May 1, 2007; 98(5): 557 - 559. [Full Text] [PDF]
|
|
|
|
 |
|
 G. Giebing, M. Tolle, J. Jurgensen, J. Eichhorst, J. Furkert, M. Beyermann, F. Neuschafer-Rube, W. Rosenthal, W. Zidek, M. van der Giet, et al. Arrestin-Independent Internalization and Recycling of the Urotensin Receptor Contribute to Long-Lasting Urotensin II-Mediated Vasoconstriction Circ. Res., September 30, 2005; 97(7): 707 - 715. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kruger, J. Graf, D. Kunz, T. Stickel, M. W. Merx, P. Hanrath, and U. Janssens Urotensin II in patients with chronic heart failure Eur J Heart Fail, June 1, 2005; 7(4): 475 - 478. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. D. Russell, P. Kearns, I. Toth, and P. Molenaar Urotensin-II-Converting Enzyme Activity of Furin and Trypsin in Human Cells in Vitro J. Pharmacol. Exp. Ther., July 1, 2004; 310(1): 209 - 214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Lim, S. Honisett, C. D. Sparkes, P. Komesaroff, A. Kompa, and H. Krum Differential Effect of Urotensin II on Vascular Tone in Normal Subjects and Patients With Chronic Heart Failure Circulation, March 16, 2004; 109(10): 1212 - 1214. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Z. Zhu, Z. J. Wang, Y. C. Zhu, L. Zhang, R. M. E. Oakley, C. W. Chung, K. W. Lim, H. S. Lee, M. L. Ozoux, W. Linz, et al. Urotensin II causes fatal circulatory collapse in anesthesized monkeys in vivo: a "vasoconstrictor" with a unique hemodynamic profile Am J Physiol Heart Circ Physiol, March 1, 2004; 286(3): H830 - H836. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Brkovic, A. Hattenberger, E. Kostenis, T. Klabunde, S. Flohr, M. Kurz, S. Bourgault, and A. Fournier Functional and Binding Characterizations of Urotensin II-Related Peptides in Human and Rat Urotensin II-Receptor Assay J. Pharmacol. Exp. Ther., September 1, 2003; 306(3): 1200 - 1209. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. M.D. Watson, G. W. Lambert, K. J. Smith, and C. N. May Urotensin II Acts Centrally to Increase Epinephrine and ACTH Release and Cause Potent Inotropic and Chronotropic Actions Hypertension, September 1, 2003; 42(3): 373 - 379. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. L. Ng, I. Loke, R. J. O'Brien, I. B. Squire, and J. E. Davies Plasma Urotensin in Human Systolic Heart Failure Circulation, December 3, 2002; 106(23): 2877 - 2880. [Abstract] [Full Text] [PDF]
|
|